SCHEMBL167827

SCHEMBL167827

O=[N+]([O-])OCCCCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30989337 0.98 CA12 (0.43)
SCHEMBL30989325 0.98 CA12 (0.43)
SCHEMBL1246014 0.98 CA12 (0.43)
SCHEMBL3765567 0.98 CA12 (0.43)
SCHEMBL3774795 0.98 CA12 (0.43)
SCHEMBL19212517 0.98 CA12 (0.43)
SCHEMBL30989339 0.98 CA12 (0.43)
SCHEMBL21810753 0.98 CA12 (0.43)
SCHEMBL21810763 0.98 CA12 (0.43)
SCHEMBL30989302 0.98 CA12 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4470565-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT OnQuality Pharmaceuticals China Ltd. (CN) 2024-12-04 EP claimed
CN-118742325-A Methods for preventing or treating diseases or conditions associated with antineoplastic agents 上海岸阔医药科技有限公司 2024-10-01 CN claimed
CN-118359595-A Nitric oxide donor type atrasentan derivative, and pharmaceutical composition and application thereof 江苏海洋大学 2024-07-19 CN claimed
CN-118359546-A Nitric oxide donor type ambrisentan derivative, and pharmaceutical composition and application thereof 江苏海洋大学 2024-07-19 CN claimed
WO-2023142996-A1 METHOD FOR PREVENTING OR TREATING DISEASE OR DISORDER ASSOCIATED WITH ANTINEOPLASTIC AGENT 上海岸阔医药科技有限公司 2023-08-03 WO claimed
CN-111601617-A Method for preventing or treating diseases related to EGFR inhibition 上海岸阔医药科技有限公司 2020-08-28 CN claimed
WO-2019201195-A1 METHOD FOR PREVENTING OR TREATING SIDE EFFECTS OF CANCER THERAPY 上海岸阔医药科技有限公司 2019-10-24 WO claimed
CN-109071750-A long-lasting cosmetic composition 生活实验公司 2018-12-21 CN claimed
US-8586790-B2 Anhydride derivatives of 2-(S)-(6-methoxy-2-naphtyl)-propanoic acid, preparation method and use thereof EVERLIGHT USA, INC. (US) 2013-11-19 US claimed
US-20120226068-A1 ANHYDRIDE DERIVATIVES OF 2-(S)-(6-METHOXY-2-NAPHTYL)-PROPANOIC ACID, PREPARATION METHOD AND USE THEREOF EVERLIGHT USA, INC. (US) 2012-09-06 US claimed
US-20080293961-A1 PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE DIPHARMA S.P.A. (IT) 2008-11-27 US claimed
US-20080146830-A1 PROCESS FOR THE MONONITRATION OF ALKANEDIOLS DIPHARMA S.P.A. (IT) 2008-06-19 US claimed
US-7335789-B2 Process for the mononitration of alkanediols DIPHARMA S.P.A. (IT) 2008-02-26 US claimed
EP-1560805-B1 A PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE DIPHARMA FRANCIS SRL (IT) 2007-07-04 EP claimed
US-20060135806-A1 Process for the purification of 1,4-butanediol mononitrate DIPHARMA S.P.A. (IT) 2006-06-22 US claimed
US-20060128983-A1 Process for the mononitration of alkanediols DIPHARMA S.P.A. (IT) 2006-06-15 US claimed
EP-1560804-A1 A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS Dipharma S.p.A. (IT) 2005-08-10 EP claimed
EP-1560805-A1 A PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE Dipharma S.p.A. (IT) 2005-08-10 EP claimed
WO-2004043898-A1 A PROCESS FOR THE MONONITRATION OF ALKANEDIOLS DIPHARMA S.P.A. (IT) 2004-05-27 WO claimed
WO-2004043897-A1 A PROCESS FOR THE PURIFICATION OF 1,4-BUTANEDIOL MONONITRATE DIPHARMA S.P.A. (IT) 2004-05-27 WO claimed